Drug intelligence / Profile preview

Maxvax

Development stage: Phase 2
Lead developer: MAXVAX Biotechnology
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Oral, Intravenous, Subcutaneous, Intraperitoneal, Intratumoral, Transdermal, Intranasal

Overview

Maxvax is a recombinant vaccine developed by MAXVAX Biotechnology Limited Liability Company, targeting the varicella zoster virus to prevent herpes zoster. The vaccine contains recombinant varicella zoster virus glycoprotein E, which is designed to elicit an immune response in vaccinated individuals. It is currently undergoing clinical evaluation for its immunogenicity and safety.

Targets

gE (VZV glycoprotein E)

Beyond the preview

Go deeper on Maxvax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maxvax.

Explore the full profile